123 related articles for article (PubMed ID: 19360150)
1. Cancer biomarker discovery and development in gastrointestinal cancers: early detection research network-a collaborative approach.
Srivastava S
Gastrointest Cancer Res; 2007; 1(4 Suppl 2):S60-3. PubMed ID: 19360150
[TBL] [Abstract][Full Text] [Related]
2. The impact of the lung EDRN-CVC on Phase 1, 2, & 3 biomarker validation studies.
Kammer MN; Deppen SA; Antic S; Jamshedur Rahman SM; Eisenberg R; Maldonado F; Aldrich MC; Sandler KL; Landman B; Massion PP; Grogan EL
Cancer Biomark; 2022; 33(4):449-465. PubMed ID: 35491773
[TBL] [Abstract][Full Text] [Related]
3. Newer markers for hepatocellular carcinoma.
Marrero JA; Lok AS
Gastroenterology; 2004 Nov; 127(5 Suppl 1):S113-9. PubMed ID: 15508074
[TBL] [Abstract][Full Text] [Related]
4. The Early Detection Research Network: A National Infrastructure to Support the Discovery, Development, and Validation of Cancer Biomarkers.
Srivastava S; Wagner PD
Cancer Epidemiol Biomarkers Prev; 2020 Dec; 29(12):2401-2410. PubMed ID: 32357955
[TBL] [Abstract][Full Text] [Related]
5. The Early Detection Research Network's Specimen reference sets: paving the way for rapid evaluation of potential biomarkers.
Feng Z; Kagan J; Pepe M; Thornquist M; Ann Rinaudo J; Dahlgren J; Krueger K; Zheng Y; Patriotis C; Huang Y; Sorbara L; Thompson I; Srivastava S
Clin Chem; 2013 Jan; 59(1):68-74. PubMed ID: 23193062
[TBL] [Abstract][Full Text] [Related]
6. Bioinformatics: biomarkers of early detection.
Crichton DJ; Mattmann CA; Thornquist M; Anton K; Hughes JS
Cancer Biomark; 2010; 9(1-6):511-30. PubMed ID: 22112493
[TBL] [Abstract][Full Text] [Related]
7. Adding Rigor to Biomarker Evaluations-EDRN Experience.
Feng Z; Pepe MS
Cancer Epidemiol Biomarkers Prev; 2020 Dec; 29(12):2575-2582. PubMed ID: 33172885
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Serum Glycoprotein Biomarker Candidates for Detection of Esophageal Adenocarcinoma and Surveillance of Barrett's Esophagus.
Shah AK; Hartel G; Brown I; Winterford C; Na R; Cao KL; Spicer BA; Dunstone MA; Phillips WA; Lord RV; Barbour AP; Watson DI; Joshi V; Whiteman DC; Hill MM
Mol Cell Proteomics; 2018 Dec; 17(12):2324-2334. PubMed ID: 30097534
[TBL] [Abstract][Full Text] [Related]
9. The early detection research network: 10-year outlook.
Srivastava S
Clin Chem; 2013 Jan; 59(1):60-7. PubMed ID: 23160065
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers in Barrett's esophagus.
Reid BJ; Blount PL; Rabinovitch PS
Gastrointest Endosc Clin N Am; 2003 Apr; 13(2):369-97. PubMed ID: 12916666
[TBL] [Abstract][Full Text] [Related]
11. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.
Marrero JA; Feng Z; Wang Y; Nguyen MH; Befeler AS; Roberts LR; Reddy KR; Harnois D; Llovet JM; Normolle D; Dalhgren J; Chia D; Lok AS; Wagner PD; Srivastava S; Schwartz M
Gastroenterology; 2009 Jul; 137(1):110-8. PubMed ID: 19362088
[TBL] [Abstract][Full Text] [Related]
12. Systematic, evidence-based discovery of biomarkers at the NCI.
Prensner JR; Chinnaiyan AM; Srivastava S
Clin Exp Metastasis; 2012 Oct; 29(7):645-52. PubMed ID: 22868876
[TBL] [Abstract][Full Text] [Related]
13. A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus.
Critchley-Thorne RJ; Duits LC; Prichard JW; Davison JM; Jobe BA; Campbell BB; Zhang Y; Repa KA; Reese LM; Li J; Diehl DL; Jhala NC; Ginsberg G; DeMarshall M; Foxwell T; Zaidi AH; Lansing Taylor D; Rustgi AK; Bergman JJ; Falk GW
Cancer Epidemiol Biomarkers Prev; 2016 Jun; 25(6):958-68. PubMed ID: 27197290
[TBL] [Abstract][Full Text] [Related]
14. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
[TBL] [Abstract][Full Text] [Related]
15. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
[TBL] [Abstract][Full Text] [Related]
16. Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma.
Zou H; Osborn NK; Harrington JJ; Klatt KK; Molina JR; Burgart LJ; Ahlquist DA
Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):830-4. PubMed ID: 15824152
[TBL] [Abstract][Full Text] [Related]
17. Biomarker development for hepatocellular carcinoma early detection: current and future perspectives.
Sengupta S; Parikh ND
Hepat Oncol; 2017 Oct; 4(4):111-122. PubMed ID: 30191058
[TBL] [Abstract][Full Text] [Related]
18. Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-γ-carboxyprothrombin.
Inagaki Y; Tang W; Makuuchi M; Hasegawa K; Sugawara Y; Kokudo N
Liver Int; 2011 Jan; 31(1):22-35. PubMed ID: 20874725
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers of Barrett's Esophagus: From the Laboratory to Clinical Practice.
Konda VJA; Souza RF
Dig Dis Sci; 2018 Aug; 63(8):2070-2080. PubMed ID: 29713984
[TBL] [Abstract][Full Text] [Related]
20. Combining des-gamma-carboxyprothrombin and alpha-fetoprotein for hepatocellular carcinoma diagnosing: an update meta-analysis and validation study.
Chen H; Chen S; Li S; Chen Z; Zhu X; Dai M; Kong L; Lv X; Huang Z; Qin X
Oncotarget; 2017 Oct; 8(52):90390-90401. PubMed ID: 29163838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
